Sorensis FAQs

The product is an inert polymer-based implant which is placed under the skin of the ear. It contains a gonadotrophin releasing hormone (GnRH) agonist which blocks hormone signals from the brain to the ovaries and suppresses the normal function of the ovaries.

Yes, the current product is biodegradable.

The current product has no effect on male cattle reproduction, but Sorensis recognises the significant need for painless castration in males. Once funding is available, this will become a research focus.

The formulation has been developed to provide contraception for 12 months and Proof of Concept (POC) efficacy studies in female cattle are ongoing. Data from these studies will guide the next phases of formulation
development.

Depending on the time since the product was administered, it may be
possible to remove but we have no data on this at this stage.

This is a common question and indicates some potential end users are
interested in this concept. Our technology partner has the capability to design multiple variations of the polymer platform so we have confidence that we could formulate such a product.

To derisk the project to improve likelihood of success, we chose the female
approach because there is much more historical data supporting our planned concept. And there is an unmet need for new technology to prevent pregnancy in heifers and cows that are surplus to herd breeding. However, given most young male cattle are castrated, there is a significant need for a non-surgical sterilization technology targeting male cattle. We have a globally recognised reproductive endocrinology expert in Professor Michael D’Occhio on the Sorensis Expert advisory Group (EAG) so we know we have the expertise to design a male focused technology.

No, the next generation polymer technology we are using is applicable to
companion and production animal species. We aim to build a portfolio
covering key unmet needs in both companion and production species.

Sorensis was started due to long term goal of the founder to provide non-
surgical fertility control for beef cattle in global cattle producing regions. This is a particularly challenging product to start a portfolio because many
companies have attempted unsuccessfully to commercialise a non-surgical
anti-fertility solution for cattle. This provides Sorensis an opportunity to be the first company to solve a long standing unmet need for the global beef industry.

Vision; We envision a world where treating animals doesn’t mean daily
interventions, lost productivity and use of painful procedures.
Mission; Exact Science engineering Enduring Solutions

At this stage, we have supportive data from both multiple laboratory
assessments and cattle studies that such duration of contraception is
feasible.

It is too early to provide realistic enduser pricing. However, while our pricing must balance commercial needs with industry realities, our intent is to remain competitive with the current costs of contraceptive solutions used by producers. At the same time, because we are leveraging next-generation polymer technology, it is possible that the final product will offer performance superior to existing alternatives.

The product is designed to be administered under the skin of the ear. Given the early stage of development, specific application systems for the product remain undefined. However, the placement of implants under the skin of the ear is a customary practice for producers, and we expect our application systems to be similar in concept to standard procedures used today.

Initial discussions with the APVMA indicate that the product will be classified as Schedule S4 in Australia and supplied through veterinarians. However, it is expected that producers will administer the product themselves.

It is likely the product will require storage between 4-8° C during storage,
shipment and before use.